Improvement in long term and visuo-spatial memory following chronic pioglitazone in mouse model of Alzheimer's disease

@article{Gupta2012ImprovementIL,
  title={Improvement in long term and visuo-spatial memory following chronic pioglitazone in mouse model of Alzheimer's disease},
  author={Rachna Gupta and Lalit Gupta},
  journal={Pharmacology Biochemistry and Behavior},
  year={2012},
  volume={102},
  pages={184-190}
}
  • Rachna Gupta, L. Gupta
  • Published 1 August 2012
  • Biology, Psychology
  • Pharmacology Biochemistry and Behavior

Figures from this paper

Effects of Chronic Administration of Pioglitazone on Learning and Memory in Rat Model of Streptozotocin-induced Alzheimer’s Disease
TLDR
PIOG administration impaired spatial learning and memory in normal rats, but improved learning andMemory in rats with STZ-induced AD, which can be useful for treatment of cognitive impairment in AD patients.
Low-dose pioglitazone can ameliorate learning and memory impairment in a mouse model of dementia by increasing LRP1 expression in the hippocampus
TLDR
The results proposed that a new therapeutic application of the PPAR-γ agonist for AD treatment should be considered at a lower dose than the conventional dose used to treat diabetes.
Strength exercise suppresses STZ‐induced spatial memory impairment and modulates BDNF/ERK‐CAMKII/CREB signalling pathway in the hippocampus of mice
TLDR
It is demonstrated that strength exercise modulated the hippocampal BDNF/ERK‐CAMKII/CREB signalling pathway and suppressed STZ‐induced spatial memory impairment in mice.
Effect of pioglitazone and simvastatin in lipopolysaccharide-induced amyloidogenesis and cognitive impairment in mice: possible role of glutamatergic pathway and oxidative stress
TLDR
It is concluded that simvastatin and pioglitazone may have a protective effect against cognitive impairment induced by LPS, through targeting the glutamatergic and inflammatory pathways, especially in patients having hypercholesterolemia and diabetes.
Protective effect of valproic acid in streptozotocin-induced sporadic Alzheimer’s disease mouse model: possible involvement of the cholinergic system
TLDR
For the first time to the authors' knowledge, VPA is capable of restoring ACh levels in ICV-STZ-injected mice, as well as normalizing both NEP levels and AChE activity and is suggested to be a promising therapeutic approach against SAD.
Investigating the Diabetic Brain: The Effects of Pioglitazone and Insulin on the Cellular Processes and Pathology of Alzheimer's Disease
TLDR
It is suggested that increasing glucose uptake in the brain alleviated AD pathology, further clarifying the role of insulin signaling in AD pathology.
Pioglitazone improves working memory performance when administered in chronic TBI
Current Progress on Peroxisome Proliferator-activated Receptor Gamma Agonist as an Emerging Therapeutic Approach for the Treatment of Alzheimer's Disease: An Update
TLDR
Peroxisome proliferator-activated receptor gamma (PPARγ) agonist improves both learning and memory along with other AD related pathology and signifies a significant new therapeutic target in treating AD.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 55 REFERENCES
Complete Rescue of Cerebrovascular Function in Aged Alzheimer's Disease Transgenic Mice by Antioxidants and Pioglitazone, a Peroxisome Proliferator-Activated Receptor γ Agonist
TLDR
These results are the first to demonstrate that late pharmacological intervention with pioglitazone not only overcomes cerebrovascular dysfunction and altered neurometabolic coupling in aged APP mice, but also counteracts cerebral oxidative stress, glial activation, and, partly, cholinergic denervation.
The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys
TLDR
The results indicate that oral administration of pioglitazone is neuroprotective when administered early after inducing a parkinsonian syndrome in rhesus monkeys and supports the concept that PPAR-γ is a viable target against neurodegeneration.
Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study.
  • G. Watson, B. Cholerton, S. Craft
  • Medicine, Psychology
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
  • 2005
TLDR
Preliminary support is provided that rosiglitazone may offer a novel strategy for the treatment of cognitive decline associated with AD, consistent with recent reports that plasma Abeta42 decreases with progression of AD.
Protective action of the peroxisome proliferator‐activated receptor‐γ agonist pioglitazone in a mouse model of Parkinson's disease
TLDR
There was little reduction of MPTP‐induced dopamine depletion, with no detectable effect on loss of TH immunoreactivity and glial response in the striatum of pioglitazone‐treated animals.
The Oral Antidiabetic Pioglitazone Protects from Neurodegeneration and Amyotrophic Lateral Sclerosis-Like Symptoms in Superoxide Dismutase-G93A Transgenic Mice
TLDR
Pio-treated transgenic mice revealed improved muscle strength and body weight, exhibited a delayed disease onset, and survived significantly longer than nontreated SOD1-G93A mice, indicating not only morphological but also functional protection of motor neurons by Pio.
Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease.
TLDR
It is demonstrated that early treatment with peroxisome-proliferator activated receptor agonists can effectively prevent ic-STZ-induced neurodegeneration and its associated deficits in learning and memory.
Study of the effect of inhibiting galanin in Alzheimer's disease induced in rats.
Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice
...
1
2
3
4
5
...